HPLC Determination of Aminopyridines Remained as Genetoxic Impurities in 3-Aminopiperidine Dihydrochloride
摘 要
在降血糖药物苯甲酸阿格列汀的合成过程中,有可能因原料的因素而引入氨基吡啶类基因毒性杂质而对上述药物的用药安全性造成影响。为此试验提出了用高效液相色谱法测定3-氨基哌啶二盐酸盐中3种氨基吡啶化合物(4-氨基吡啶、3-氨基吡啶和2-氨基吡啶)的方法。称取试样0.3 g,用磷酸盐缓冲溶液(pH 7.0)-甲醇(90+10)混合溶液超声溶解并定容至10.0 mL。选择Shim-pack Scepter C18色谱柱作为分离柱,用pH 7.0的磷酸盐缓冲溶液和甲醇(90+10)的混合溶液等度洗脱,流量为0.5 mL·min-1,柱温为35℃,检测波长为280 nm,进样量10 μL。在选定的条件下,上述3种化合物可达到很好的分离,4-氨基吡啶、3-氨基吡啶和2-氨基吡啶间的分离度分别为30.3,8.4,其检出限(3S/N)分别为0.028 9,0.071 1,0.070 2 mg·L-1。在3个浓度水平上对3种化合物进行回收试验,测得回收率依次为101%,98.4%,97.2%。重复性和重现性试验所测得3种化合物测定值的相对标准偏差(n=6)分别依次为1.5%,0.90%,0.70%和6.2%,3.0%,2.2%。样品加标溶液和对照品溶液在室温下放置24 h内稳定性良好。
Abstract
Aminopyridines remained in 3-aminopiperidine dihydrochloride, which was an important compound used in the synthesis of the diabetic drug-alogliptin benzoate, might lead to un-safety of using of the drug due to their genetoxicity. Hence, a method for simultaneous determination of 3 aminopyridines (i.e., 4-aminopyridine, 3-aminopyridine and 2-aminopyridine) by HPLC was tested and proposed. 0.3 g of the sample was taken and dissolved with a mixture of phosphate buffer solution (pH 7.0) and methanol (90+10) and the volume of the solution was made up to 10.0 mL with the same buffer-CH3OH mixture. Shim-pack Scepter C18 chromatographic column was chosen as separation column. Mixture of phosphate buffer solution and CH3OH (90+10) was used for isometric elution at a flow-rate of 0.5 mL·min-1 and keeping the column temperature at 35 ℃. Detections were made at the wavelength of 280 nm. Volume taken for sample injection was 10 μL. Under the optimum chromatographic condition, the 3 aminopyridines were separated very well, giving values of resolutions between 4-aminopyridine, 3-aminopyridine and 2-aminopyridine 30.0, and 8.4 respectively. Detection limits (3S/N) found for the 3 compounds were 0.028 9, 0.071 1, 0.070 2 mg·L-1 respectively. Test for recovery was made by addition of standards at 3 concentration levels, giving values of average recoveries 101%, 98.4% and 97.2% respectively. Values of RSDs (n=6) for repeatability found were 1.5%, 0.90% and 0.70%, and for reproducibility found were 6.2%, 3.0% and 2.2% for 4-aminopyridine, 3-aminopyridine and 2-aminopyridine respectively. The sample solution with addition of standard solutions and the reference solutions were found stable within 24 h under room temperature.
中图分类号 O652.63 DOI 10.11973/lhjy-hx201912006
所属栏目 工作简报
基金项目 江苏省博士后科研资助计划项目(2018K265C)
收稿日期 2019/4/27
修改稿日期
网络出版日期
作者单位点击查看
备注董淑波,高级工程师,博士,主要从事新药研发工作,456shu@163.com
引用该论文: DONG Shubo,YANG Hanyue,XU Liang,CHEN Xuemin. HPLC Determination of Aminopyridines Remained as Genetoxic Impurities in 3-Aminopiperidine Dihydrochloride[J]. Physical Testing and Chemical Analysis part B:Chemical Analysis, 2019, 55(12): 1396~1400
董淑波,杨汉跃,徐亮,陈学民. 高效液相色谱法测定3-氨基哌啶二盐酸盐中氨基吡啶类基因毒性杂质的含量[J]. 理化检验-化学分册, 2019, 55(12): 1396~1400
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
参考文献
【1】FENG J, ZHANG Z Y, WALLACE M B, et al. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV[J]. Journal of Medicinal Chemistry, 2007,50(10):2297-2300.
【2】PRATLEY R E. Alogliptin: A new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes[J]. Expert Opinionon Pharmacotherapy, 2009,10(3):503-512.
【3】SYRRX I, FENG J, GWALTNEY SL, et al. Dipeptidyl peptidase inhibitors: WO 2005095381A1[P]. 2005-10-13.
【4】Takeda Pharmaceutical. Dipeptidyl peptidase inhibitors: WO 2007035629A2[P]. 2006-09-15.
【5】SAMUEL H J, MEEK G A. Method for producing 3-aminopiperidine diastereomer: WO 2007075630[P]. 2007-07-05.
【6】KAREN R, MATTHIAS H. Process for preparation of optically active n-protected 3-aminopyrrolidin or optically active n-protected 3-aminopiperidine and corresponding ketones by optical resolution of the racemic amine mixtures employing a bacterial omega-transaminase: WO 2008028654[P]. 2008-03-13.
【7】马磊,马玉楠,陈震,等.遗传毒性杂质的警示结构[J].中国新药杂志, 2014,23(18):2106-2111.
【8】RAILLARD S P, BERCU J, BAERTSCHI S W, et al. Prediction of drug degradation pathways leading to structural alerts for potential genotoxic impurities[J]. Organic Process Research & Development, 2010,14(4):1015-1020.
【9】SNODIN D J. Genotoxic impurities: From structural alerts to qualification[J]. Organic Process Research and Development, 2010,14(4):960-976.
【10】ANDUKURIV R, DRINCIC A, RENDELL M. Alogliptin: A new addition to the class of DPP-4 inhibitors[J]. Diabetes,Metabolic Syndromeand Obesity: Targets and Therapy, 2009,2:117-126.
【11】International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk[EB/OL].[2019-04-27]. http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html.
【12】DONG S B, YAN Z Y, YANG H Y. A sensitive precolumn derivatization method for determination of piperazine in vortioxetine hydrobromide using a C8 column and high-performance liquid chromatography-mass spectrometry[J]. Analytical Sciences, 2016,32(12):1333-1338.
【13】张存彦.HPLC法测定4-氨基吡啶的含量[J].生物化工, 2017,3(1):17-18.
【14】于新颖,吴雨川,多凯.高效液相色谱法检查氯诺昔康中的有关物质及2-氨基吡啶[J].黑龙江医药, 2014,27(2):224-226.
【2】PRATLEY R E. Alogliptin: A new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes[J]. Expert Opinionon Pharmacotherapy, 2009,10(3):503-512.
【3】SYRRX I, FENG J, GWALTNEY SL, et al. Dipeptidyl peptidase inhibitors: WO 2005095381A1[P]. 2005-10-13.
【4】Takeda Pharmaceutical. Dipeptidyl peptidase inhibitors: WO 2007035629A2[P]. 2006-09-15.
【5】SAMUEL H J, MEEK G A. Method for producing 3-aminopiperidine diastereomer: WO 2007075630[P]. 2007-07-05.
【6】KAREN R, MATTHIAS H. Process for preparation of optically active n-protected 3-aminopyrrolidin or optically active n-protected 3-aminopiperidine and corresponding ketones by optical resolution of the racemic amine mixtures employing a bacterial omega-transaminase: WO 2008028654[P]. 2008-03-13.
【7】马磊,马玉楠,陈震,等.遗传毒性杂质的警示结构[J].中国新药杂志, 2014,23(18):2106-2111.
【8】RAILLARD S P, BERCU J, BAERTSCHI S W, et al. Prediction of drug degradation pathways leading to structural alerts for potential genotoxic impurities[J]. Organic Process Research & Development, 2010,14(4):1015-1020.
【9】SNODIN D J. Genotoxic impurities: From structural alerts to qualification[J]. Organic Process Research and Development, 2010,14(4):960-976.
【10】ANDUKURIV R, DRINCIC A, RENDELL M. Alogliptin: A new addition to the class of DPP-4 inhibitors[J]. Diabetes,Metabolic Syndromeand Obesity: Targets and Therapy, 2009,2:117-126.
【11】International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk[EB/OL].[2019-04-27]. http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html.
【12】DONG S B, YAN Z Y, YANG H Y. A sensitive precolumn derivatization method for determination of piperazine in vortioxetine hydrobromide using a C8 column and high-performance liquid chromatography-mass spectrometry[J]. Analytical Sciences, 2016,32(12):1333-1338.
【13】张存彦.HPLC法测定4-氨基吡啶的含量[J].生物化工, 2017,3(1):17-18.
【14】于新颖,吴雨川,多凯.高效液相色谱法检查氯诺昔康中的有关物质及2-氨基吡啶[J].黑龙江医药, 2014,27(2):224-226.
相关信息